Why the study?
Does intensive multifactorial risk factor management by a nurse practitioner reduce the composite of myocardial infarction, stroke, and cardiovascular mortality in patients with chronic kidney disease?
Does intensive multifactorial risk factor management by a nurse practitioner reduce the composite of myocardial infarction, stroke, and cardiovascular mortality in patients with chronic kidney disease?
The MASTERPLAN study is designed to determine if a nurse practitioner-led multifactorial intervention can reduce cardiovascular events in patients with chronic kidney disease.
Tests nurse-led multifactorial management for CV events in CKD; extends prior data with dedicated RCT design.
BACKGROUND: Chronic kidney disease (CKD) is an established risk factor for cardiovascular disease (CVD). In addition, patients with renal disease are exposed to a myriad of risk factors that increase their risk even further. The treatment of risk factors in these patients is paramount to reducing cardiovascular risk and for attenuating renal failure progression. It is well known that lifestyle interventions are difficult, and that medical treatment targets are seldom met. A multifactorial approach with the aid of nurse practitioners has shown to be beneficial for achieving treatment goals and reducing events in patients with diabetes mellitus and with heart failure. We propose that this will also hold for the CKD population. TRIAL DESIGN: A multicenter randomized clinical trial will be performed to study whether intensive medical care delivered by a nurse practitioner and a nephrologist will reduce cardiovascular risk compared to care provided by the nephrologist alone. The acronym MASTERPLAN describes the study: Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Eight hundred patients will be randomized to physician care or nurse practitioner support. For all patients the same set of guidelines and treatment goals will apply. Both groups will receive treatment according to current guidelines and have access to specific cardioprotective medication. Nurse practitioners will intensify therapy by promoting lifestyle intervention, and meticulous implementation of relevant guidelines. Patients will be followed-up for 5 yrs after baseline. Primary endpoints are all-cause mortality, cardiovascular morbidity and cardiovascular mortality.
No takes yet. Share an insight, caveat, or question.
Zuilen et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: